WEBULL
News
RANI
1.340
+5.51%
0.070
Weekly Report: what happened at RANI last week (0202-0206)?
Weekly Report · 1d ago
Weekly Report: what happened at RANI last week (0126-0130)?
Weekly Report · 02/02 10:37
Rani Therapeutics Names Alireza Javadi Chief Technical Officer
NASDAQ · 01/28 12:32
Rani Therapeutics Promotes Alireza Javadi to Chief Technical Officer
Reuters · 01/28 12:01
RANI THERAPEUTICS ANNOUNCES THE PROMOTION OF ALIREZA JAVADI, PH.D. TO CHIEF TECHNICAL OFFICER
Reuters · 01/28 12:00
Press Release: Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
Dow Jones · 01/28 12:00
Rani Therapeutics Unveils Oral Biologics Platform Targeting Injection-Free Treatments
Reuters · 01/27 16:23
Weekly Report: what happened at RANI last week (0119-0123)?
Weekly Report · 01/26 10:37
Largest borrow rate increases among liquid names
TipRanks · 01/23 13:45
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Ardelyx (ARDX) and AxoGen (AXGN)
TipRanks · 01/21 16:20
Weekly Report: what happened at RANI last week (0112-0116)?
Weekly Report · 01/19 10:45
Largest borrow rate increases among liquid names
TipRanks · 01/16 13:45
Weekly Report: what happened at RANI last week (0105-0109)?
Weekly Report · 01/12 10:43
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cartesian Therapeutics (RNAC), Rani Therapeutics Holdings (RANI) and Haemonetics (HAE)
TipRanks · 01/09 19:51
H.C. Wainwright Sticks to Their Buy Rating for Rani Therapeutics Holdings (RANI)
TipRanks · 01/09 11:36
Rani Therapeutics Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
Dow Jones · 01/09 11:29
HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target
Benzinga · 01/09 11:19
Rani Therapeutics Initiated Phase 1 Trial of RT-114, an Orally Administered Ranipill Capsule Containing GLP-1/GLP-2 Dual Agonist, PG-102, for Obesity
Benzinga · 01/08 12:14
Rani Therapeutics initiates Phase 1 study of RT-114 RaniPill
TipRanks · 01/08 12:10
Rani Therapeutics Launches Phase 1 Trial of Oral GLP-1/GLP-2 Agonist for Obesity Treatment
Reuters · 01/08 12:01
More
Webull provides a variety of real-time RANI stock news. You can receive the latest news about Rani Therapeutics Holdings, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RANI
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).